APRE Aprea Therapeutics Inc

Price (delayed)

$6.28

Market cap

$23.47M

P/E Ratio

0.51

Dividend/share

N/A

EPS

$12.34

Enterprise value

-$1.93M

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor ...

Highlights
Aprea Therapeutics's revenue has soared by 128% from the previous quarter
The company's gross profit has surged by 128% QoQ
The quick ratio has contracted by 26% YoY and by 13% from the previous quarter
The equity has contracted by 24% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of APRE
Market
Shares outstanding
3.74M
Market cap
$23.47M
Enterprise value
-$1.93M
Valuations
Price to earnings (P/E)
0.51
Price to book (P/B)
1.16
Price to sales (P/S)
41.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.39
Earnings
Revenue
$569,156
EBIT
-$14.44M
EBITDA
-$14.44M
Free cash flow
-$12.46M
Per share
EPS
$12.34
Free cash flow per share
-$3.34
Book value per share
$5.43
Revenue per share
$0.15
TBVPS
$6.9
Balance sheet
Total assets
$25.77M
Total liabilities
$5.48M
Debt
$0
Equity
$20.29M
Working capital
$21.47M
Liquidity
Debt to equity
0
Current ratio
6.15
Quick ratio
6.1
Net debt/EBITDA
1.76
Margins
EBITDA margin
-2,537.6%
Gross margin
100%
Net margin
-2,334.3%
Operating margin
-2,538.6%
Efficiency
Return on assets
-45.6%
Return on equity
-55.5%
Return on invested capital
N/A
Return on capital employed
-66.9%
Return on sales
-2,537.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
7.76%
1 week
6.26%
1 month
16.51%
1 year
-9.25%
YTD
33.62%
QTD
33.62%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$569,156
Gross profit
$569,156
Operating income
-$14.45M
Net income
-$13.29M
Gross margin
100%
Net margin
-2,334.3%
Aprea Therapeutics's revenue has soared by 128% from the previous quarter
The company's gross profit has surged by 128% QoQ
Aprea Therapeutics's net income has surged by 89% YoY and by 6% QoQ
Aprea Therapeutics's operating income has soared by 88% YoY and by 4.5% from the previous quarter

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
0.51
P/B
1.16
P/S
41.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.39
APRE's EPS has surged by 112% year-on-year and by 13% since the previous quarter
APRE's P/B is 90% above its last 4 quarters average of 0.6
The equity has contracted by 24% YoY and by 13% from the previous quarter
Aprea Therapeutics's revenue has soared by 128% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity has surged by 90% YoY
Aprea Therapeutics's ROA has soared by 82% YoY
APRE's return on sales has surged by 58% since the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The company's total liabilities rose by 39% QoQ and by 37% YoY
The current ratio has decreased by 27% YoY and by 15% from the previous quarter
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
The equity has contracted by 24% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.